Chung Sang-Wan
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.
Biomedicines. 2021 Jun 30;9(7):757. doi: 10.3390/biomedicines9070757.
Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis.
系统性血管炎是一组以血管免疫介导性炎症为特征的多种疾病。目前用于治疗血管炎的药物,如糖皮质激素和烷化剂,都伴有显著的副作用。此外,由于缺乏可靠的疾病活动标志物,小血管和大血管血管炎的管理都具有挑战性。最近的研究加深了我们对小血管和大血管血管炎发病机制的理解,这促使了能够靶向炎症级联反应关键细胞因子和细胞效应器的新型生物疗法的开发。预计这些新型治疗方法将为系统性血管炎患者带来更有效、毒性更小的治疗方案。